The invention relates to a liquid applicator, for administering liquids, including vaccines, to animals. In particular, the applicator is useful for delivering liquids to mouths of animals.

Described is a microneedle device, preferably a controlled release device, for delivery of liothyronine (LT3 or salt thereof) to a patient with hypothyroidism and/or who is not pregnant. The microneedle device contains LT3 or salt thereof in an effective amount to maintain normal, stable levels, in the serum, of free and/or total T3. The microneedle device includes at least two components: multi-dimensional array of microneedle(s) and a substrate to which the base of the microneedle(s) are secured or integrated. The microneedles contain LT3 or salt thereof as well as a biodegradable and/or biodissolvable polymer, such as polyvinyl pyrrolidone for controlled release of LT3 or salt thereof. Also described are methods of making and using the microneedle device.

A treatment device of a cerebrovascular disorder capable of reliably controlling an oxygen concentration of a brain tissue so as not to be excessively high while efficiently supplying oxygen to the brain is provided. The treatment device of a cerebrovascular disorder includes: a main body including an injection unit that is to be inserted into a living body and injects a fluid; oxygen concentration measurement units disposed at two or more locations in the living body; and a flow rate adjustment unit that adjusts a flow rate of the fluid to be injected by the injection unit, in which the flow rate adjustment unit adjusts the flow rate of the fluid to be injected by the injection unit according to oxygen concentrations at two or more locations in the living body measured by the oxygen concentration measurement units.

Provided herein are methods and compositions for treating bone osteonecrosis comprising: at least one of a Gelatin tyramine (GT), a gelatin-heparin tyramine (GHT), a gelatin methacryloyl (GelMa), a gelatin acryloyl (GelAC), collagen, or a hydrogel-forming peptide that can be formed ex vivo or in situ for the treatment of bone osteonecrosis; at least one bone growth promoting agent or a macrophage depletion reagent; and optionally one or more pharmaceutically acceptable carriers.

A circular stapling instrument includes an adapter assembly having a tubular body, a shell assembly disposed on a distal portion of the tubular body, and a seal assembly supported on the tubular body. The seal assembly includes an inflatable member disposed proximal of the shell assembly, wherein the inflatable member includes a first diameter when in a deflated condition and a second diameter when in an inflated condition, the second diameter being larger than the first diameter.

The present invention discloses a nano-armored single cell product, comprising a liposome and probiotics encapsulated by the liposome, wherein the probiotics are fermented to produce gamma-aminobutyric acid (GABA) that alleviates the activation of an inflammatory response in substantia nigra inducedin a MPTP induced PD model, thus mitigating an inflammatory injury to dopaminergic neurons in substantia nigra and having a neuroprotective effect; encapsulation of the probiotics by the liposome can protect the probiotics from strong acids and digestive enzymes in gastric acid.

Methods and apparatus to reduce deadspace in syringes and other devices with the use of volume displacing members that occupy space within one or more interior spaces of such devices. The volume displacing members are also equipped with one or more internal flow passages that facilitate a flow of a fluid through it. The volume displacing members are also adapted to cooperate with features of the devices that house them to form air-tight and liquid-tight seals that at least partially determine a fluid pathway through the devices.

The invention relates to a liquid applicator, for administering liquids, including vaccines, to animals. In particular, the applicator is useful for delivering liquids to mouths of animals.

A treatment system for performing a treatment on a patient may include a treatment fluid preparation device having a pump connected by a fluid channel to a reservoir of a source fluid, the pump conveying the source fluid from the reservoir, through a filter, and combining the source fluid with a concentrate by pumping the source fluid with the concentrate to form a treatment fluid in a batch container. The treatment fluid preparation device may have a controller that controls a heater, the pump, and a memory. The controller starts the heater to warm the treatment fluid in the batch container at a time that is responsive to the treatment time stored in the memory. The controller also detects a pressure property of the filter to determine its integrity and outputs an indication of a failed batch if the pressure property indicates the integrity of the filter is insufficient.

A treatment system for performing a treatment on a patient may include a treatment fluid preparation device having a pump connected by a fluid channel to a reservoir of a source fluid, the pump conveying the source fluid from the reservoir, through a filter, and combining the source fluid with a concentrate by pumping the source fluid with the concentrate to form a treatment fluid in a batch container. The treatment fluid preparation device may have a controller that controls a heater, the pump, and a memory. The controller starts the heater to warm the treatment fluid in the batch container at a time that is responsive to the treatment time stored in the memory. The controller also detects a pressure property of the filter to determine its integrity and outputs an indication of a failed batch if the pressure property indicates the integrity of the filter is insufficient.